A day after getting beaten down with the rest of the market, three-fourths of this year’s VC-backed IPOs posted gains in today’s market rebound.

Of the 38 VC-backed companies that have gone public on U.S. exchanges this year, 28 saw their share prices increase today, while nine experienced declines and one remained flat, according to data from Thomson Reuters (publisher of peHUB). That stands in stark contrast to yesterday, when 36 of the stocks lost value and two remained flat.

The biggest gainers in terms of dollars were LinkedIn (NYSE: LNKD), which shot up

Venture-backed IPOs have gotten off to a strong start this year. So far, a dozen venture-backed companies have gone public, raising just over $1 billion in proceeds, according to Thomson Reuters (publisher of peHUB). For the same period a year earlier, just three companies went public, raising $379.5 million.

Which VC-backed stock has cratered 35 percent since its offering? Which one has soared nearly 49 percent? Check out our slideshow to find out.

(If you like the data, consider subscribing to Venture Capital Journal. In each issues, VCJ publishes even more detailed profiles of every VC-backed IPO, including the share holdings of VC backers. Click here for a free trial.)

Endocyte Inc., a West Lafayette, Ind.-based developer of receptor-targeted therapeutics for the treatment of cancer and autoimmune diseases, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol ECYT, with RBC Capital Markets and Leerink Swann serving as co-lead underwriters. The company has raised around $61 million in [...]

Endocyte Inc., a West Lafayette, Ind.-based developer of receptor-targeted therapeutics for the treatment of cancer and autoimmune diseases, has raised $26 million in new Series C funding. Clarian Health Ventures was joined by return backersSanderling Ventures, Burrill & Co., American Bailey Ventures, Blue Chip Venture Co., and Triathlon Medical Ventures. Endocyte has raised around $61 million in total VC funding since 2001.